Oncology Institute (TOI) Amortization of Deferred Charges (2021 - 2026)

Oncology Institute (TOI) has 6 years of Amortization of Deferred Charges data on file, last reported at $1.2 million in Q1 2026.

• For the quarter ending Q1 2026, Amortization of Deferred Charges fell 75.15% year-over-year to $1.2 million; the trailing twelve-month figure through Mar 2026 stood at $4.7 million (down 50.97% YoY), and the FY2025 full-year result was $8.4 million, up 32.91% from the prior year.
• Amortization of Deferred Charges for Q1 2026 stood at $1.2 million, roughly flat from $1.2 million in the prior quarter.
• Across five years, Amortization of Deferred Charges topped out at $4.9 million in Q1 2025 and bottomed at $892000.0 in Q3 2022.
• The 5-year median for Amortization of Deferred Charges is $1.6 million (2022), against an average of $1.6 million.
• The widest annual swing landed in 2022, when Amortization of Deferred Charges jumped 4855.56%; it then sank 75.15% in 2026.
• A 5-year view of Amortization of Deferred Charges shows it stood at $1.6 million in 2022, then advanced by 1.29% to $1.6 million in 2023, then gained by 1.4% to $1.6 million in 2024, then retreated by 24.4% to $1.2 million in 2025, then increased by 0.5% to $1.2 million in 2026.
• The last three Amortization of Deferred Charges figures came in at $1.2 million (Q1 2026), $1.2 million (Q4 2025), and $1.2 million (Q3 2025), per Business Quant data.

Peer Comparison